Cytomedix’s AutoloGel™ System Highlighted
in Hair Transplant Trade Journal
Rockville, MD, . (February
23, 2010) – Cytomedix, Inc. (AMEX:
GTF) a leading developer of biologically active
regenerative therapies for wound care, inflammation and
angiogenesis, today announced that the Company’s lead
product, the AutoloGel™ System, is highlighted in the
current issue of “Hair Transplant Forum International,” the
bi-monthly publication of the International Society of Hair
Restoration Surgery. The article is authored by
internationally renowned hair restoration specialist, Robert
J. Reese, D.O., and is titled, “Autologous Platelet Rich
Plasma (PRP): What Do We Know? Important Concepts Relevant
To Hair Restoration Surgery.”
According to the article, “Relating to hair restoration, the
application of PRP has been evaluated as a treatment to both
speed wound healing and foster hair growth. Both of these
endpoints relate to the delivery of growth factor, cytokine,
and chemokine activities, and based upon available past and
present data, this author suggests that PRP containing
physiologic concentrations of platelets is most
appropriate.”
In his review, Dr. Reese discusses several factors that
affect his choice of Cytomedix’s AutoloGel System as the
optimal PRP therapy for wounds associated with hair
restoration surgery including:
- The AutoloGel System is
the only PRP system that is FDA cleared for the care of
wounds.
- The AutoloGel System
produces an end product derived from physiologic
concentrations of platelets that is activated with
thrombin to produce active PRP gel.
- The AutoloGel System
produces a PRP that has no or minimal contaminating red
cells or leukocytes. The presence of which is an obvious
aesthetic consideration and recent data supports that
contaminating leukocytes may detrimentally impact
performance.
The author recommends that,
“for purposes of safety, efficacy, and standardization
across the hair restoration community, investigators
consider the Cytomedix AutoloGel System, which produces
activated PRP gel from physiological concentrations of
platelets with little or no contaminating red cells or
leukocytes.”
“Dr. Reese’s article makes a strong clinical case for the
inclusion of the AutoloGel System in hair transplantation
surgery. We concur with his findings and believe this
represents an attractive market opportunity for the
AutoloGel System,” noted Martin Rosendale, Chief Executive
Officer of Cytomedix.
The full article is available at
http://www.cytomedix.com/docs/reese_article_prp.pdf
About Cytomedix
Cytomedix develops, sells
and licenses regenerative biological therapies including the
AutoloGel™ System, a device for the production of Platelet
Rich Plasma ("PRP") gel derived from the patient's own
blood. The AutoloGel™ System is cleared by the U.S. Food and
Drug Administration for use on a variety of exuding wounds.
The Company is pursuing a multi-faceted strategy to
penetrate the chronic wound market with its AutoloGel™
System. The Company is also moving forward with the
development of other product candidates in its pipeline.
Most notably is its CT-112 product, an anti-inflammatory
peptide that has shown promise in preclinical testing.
Additional information regarding Cytomedix is available at
www.cytomedix.com.
About Hair Transplant
Forum International
Hair Transplant Forum
International is a privately published newsletter of the
International Society of Hair Restoration Surgery. Its
contents are solely the opinions of the authors and are not
formally “peer reviewed” before publication. To facilitate
the free exchange of information, a less stringent standard
is employed to evaluate the scientific accuracy of the
letters and articles published in the Forum. The standard of
proof required for letters and articles is not to be
compared with that of formal medical journals. The
newsletter was designed to be and continues to be a printed
forum where specialists and beginners in hair restoration
techniques can exchange thoughts, experiences, opinions, and
pilot studies on all matters relating to hair restoration.
Safe Harbor Statement
Statements contained in
this communication not relating to historical facts are
forward-looking statements that are intended to fall within
the safe harbor rule for such statements under the Private
Securities Litigation Reform Act of 1995. The information
contained in the forward-looking statements is inherently
uncertain, and Cytomedix’s actual results may differ
materially due to a number of factors, many of which are
beyond Cytomedix’s ability to predict or control, including
among others, viability and effectiveness of the Company’s
sales approach and overall marketing strategies, the outcome
of development or regulatory review of CT-112, commercial
success or acceptance by the medical community, competitive
responses, the Company's ability to raise additional capital
and to continue as a going concern, its ability to
successfully commercialize its product in Japan under the
terms of the license agreement, and Cytomedix's ability to
execute on its strategy to market the AutoloGel™ System as
contemplated. These forward-looking statements are subject
to known and unknown risks and uncertainties that could
cause actual events to differ from the forward-looking
statements. More information about some of these risks and
uncertainties may be found in the reports filed with the
Securities and Exchange Commission by Cytomedix, Inc.
Cytomedix operates in a highly competitive and rapidly
changing business and regulatory environment, thus new or
unforeseen risks may arise. Accordingly, investors should
not place any reliance on forward-looking statements as a
prediction of actual results. Except as is expressly
required by the federal securities laws, Cytomedix
undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new
information, changed circumstances or future events or for
any other reason.
|
